8-K Announcements
6Material company update
Apr 8, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Jan 26, 2026·SEC
Autolus Therapeutics plc(AUTL)Earnings, Financials & Key Ratios
AUTL•NASDAQ
$1.70
$434M mkt cap·Price updated May 6, 2026
AboutAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Show more
- Revenue$10M+496.0%
- EBITDA-$234M-35.0%
- Net Income-$221M-5.9%
- EPS (Diluted)-0.87+27.5%
- Gross Margin-1293.48%-1393.5%
- EBITDA Margin-2309.39%+77.4%
- Operating Margin-2385.63%+77.5%
- Net Margin-2180.45%+82.2%
- ROE-81.91%+19.4%
- ROIC-204.08%
- Debt/Equity0.12-74.1%
- Interest Coverage-25.98-551.5%
AUTL Key Insights
Autolus Therapeutics plc (AUTL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 28.3%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 46.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AUTL Price & Volume
Autolus Therapeutics plc (AUTL) stock price & volume — 10-year historical chart
Loading chart...
AUTL Growth Metrics
Autolus Therapeutics plc (AUTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years28.33%
3 Years88.66%
TTM406.67%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.58%
Return on Capital
10 Years-54%
5 Years-56.71%
3 Years-42.36%
Last Year-45.87%
AUTL Recent Earnings
Autolus Therapeutics plc (AUTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 6/12 qtrs (67%)
Q2 2026Latest
Mar 27, 2026EPS
$0.34
Est $0.26
-30.8%
Revenue
$24M
Est $24M
+1.6%
Q4 2025
Nov 12, 2025EPS
$0.30
Est $0.23
-30.4%
Revenue
$21M
Est $24M
-13.2%
Q3 2025
Aug 12, 2025EPS
$0.18
Est $0.24
+25.0%
Revenue
$21M
Est $21M
-0.7%
Q2 2025
May 8, 2025EPS
$0.26
Est $0.24
-8.3%
Revenue
$9M
Est $2M
+309.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 27, 2026 | $0.34vs $0.26-30.8% | $24Mvs $24M+1.6% |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.23-30.4% | $21Mvs $24M-13.2% |
| Q3 2025 | Aug 12, 2025 | $0.18vs $0.24+25.0% | $21Mvs $21M-0.7% |
| Q2 2025 | May 8, 2025 | $0.26vs $0.24-8.3% | $9Mvs $2M+309.1% |
Based on last 12 quarters of dataView full earnings history →
AUTL Peer Comparison
Autolus Therapeutics plc (AUTL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRSP | 5.17B | 55.08 | -8.51 | -89.97% | -13.29% | -25.49% | 0.11 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 ALLO | 529.95M | 2.31 | -2.66 | -100% | -57.07% | 0.26 | ||
 CABA | 381.44M | 3.73 | -2.27 | -121.73% | 0.24 | |||
 LEGN | 5.35B | 28.96 | -8.99 | 64.47% | -28.83% | -29.22% | 0.41 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare AUTL vs Peers
Autolus Therapeutics plc (AUTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AUTL Income Statement
Autolus Therapeutics plc (AUTL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'16 | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.21M | 1.69M | 1.05M | 2.91M | 1.72M | 1.51M | 6.19M | 1.7M | 10.12M | 51.13M |
| Revenue Growth % | 1187.83% | 39.69% | -38.26% | 178.19% | -41.02% | -12.13% | 311.02% | -72.59% | 496% | 406.67% |
| Cost of Goods Sold | 478K | 1.01M | 48.3M | 105.42M | 134.89M | 0 | 0 | 0 | 141.02M | 209.34M |
| COGS % of Revenue | 39.44% | 59.6% | 4620.4% | 3625.1% | 7865.19% | - | - | - | 1393.48% | - |
| Gross Profit | 734K▲ 0% | 684K▼ 6.8% | -47.25M▼ 7008.4% | -102.51M▼ 116.9% | -133.17M▼ 29.9% | 1.51M▲ 101.1% | 6.19M▲ 311.0% | 1.7M▼ 72.6% | -130.9M▼ 7809.1% | -158.22M▲ 0% |
| Gross Margin % | 60.56% | 40.4% | -4520.4% | -3525.1% | -7765.19% | 100% | 100% | 100% | -1293.48% | -309.45% |
| Gross Profit Growth % | 679.92% | -6.81% | -7008.43% | -116.94% | -29.91% | 101.13% | 311.02% | -72.59% | -7809.07% | - |
| Operating Expenses | 15.59M | 25.11M | 41.48M | 145.07M | 169.96M | 141.88M | 149.09M | 181.4M | 110.53M | 281.29M |
| OpEx % of Revenue | 1286.14% | 1483.22% | 3968.39% | 4988.65% | 9910.2% | 9414.8% | 2406.96% | 10683.1% | 1092.15% | - |
| Selling, General & Admin | 5.15M | 9.1M | 16.85M | 39.45M | 34.97M | 31.86M | 31.9M | 46.74M | 0 | 138.56M |
| SG&A % of Revenue | 425.08% | 537.45% | 1611.51% | 1356.67% | 2039.18% | 2114.47% | 515% | 2752.94% | - | - |
| Research & Development | 10.44M | 16.01M | 24.64M | 105.62M | 134.99M | 110.84M | 117.35M | 130.48M | 158.14M | 132.59M |
| R&D % of Revenue | 861.06% | 945.78% | 2356.89% | 3631.98% | 7871.02% | 7354.94% | 1894.64% | 7684.39% | 1562.61% | - |
| Other Operating Expenses | -26K | -46K | 3.97M | 0 | 0 | -823K | -166K | 4.17M | -47.61M | 1000K |
| Operating Income | -14.38M▲ 0% | -23.42M▼ 62.9% | -57.53M▼ 145.7% | -247.58M▼ 330.3% | -303.13M▼ 22.4% | -140.37M▲ 53.7% | -142.89M▼ 1.8% | -179.7M▼ 25.8% | -241.43M▼ 34.3% | -439.5M▲ 0% |
| Operating Margin % | -1186.14% | -1383.22% | -5503.74% | -8513.76% | -17675.39% | -9314.8% | -2306.96% | -10583.1% | -2385.63% | -859.61% |
| Operating Income Growth % | -77.34% | -62.9% | -145.68% | -330.33% | -22.44% | 53.69% | -1.79% | -25.76% | -34.35% | - |
| EBITDA | -13.9M | -22.41M | -55.82M | -243.02M | -297.57M | -131.92M | -135.47M | -173.14M | -233.71M | -427.47M |
| EBITDA Margin % | -1146.7% | -1323.63% | -5340.26% | -8356.81% | -17350.79% | -8753.55% | -2187.13% | -10196.47% | -2309.39% | -836.08% |
| EBITDA Growth % | -210.91% | -61.24% | -149.11% | -335.33% | -22.45% | 55.67% | -2.69% | -27.8% | -34.99% | -116.18% |
| D&A (Non-Cash Add-back) | 478K | 1.01M | 1.71M | 4.56M | 5.57M | 8.46M | 7.42M | 6.57M | 7.72M | 12.03M |
| EBIT | -14.38M | -23.42M | -52.03M | -141.96M | -168.15M | -140.93M | -139.66M | -163.34M | -240.79M | -262.94M |
| Net Interest Income | 75K | 84K | 4.11M | 2.54M | 536K | -843K | -7.2M | -31.56M | 23.06M | 40.2M |
| Interest Income | 75K | 84K | 4.12M | 2.54M | 536K | 262K | 1.71M | 13.51M | 32.35M | 30.03M |
| Interest Expense | 0 | 0 | 12.67K | 0 | 0 | 1.1M | 8.9M | 45.07M | 9.29M | -10.17M |
| Other Income/Expense | 49K | 38K | 6.91M | 138.89M | 136.88M | -1.66M | -5.67M | -28.7M | 22.29M | 219.31M |
| Pretax Income | -14.33M▲ 0% | -23.38M▼ 63.2% | -36.33M▼ 55.4% | -108.69M▼ 199.2% | -166.26M▼ 53.0% | -142.04M▲ 14.6% | -148.57M▼ 4.6% | -208.4M▼ 40.3% | -219.13M▼ 5.1% | -220.19M▲ 0% |
| Pretax Margin % | -1182.1% | -1380.98% | -3475.09% | -3737.62% | -9694.29% | -9425.22% | -2398.56% | -12273.38% | -2165.36% | -430.66% |
| Income Tax | -1.78M | -3.65M | -5.21M | 15.16M | -24.16M | 58K | 272K | -19K | 1.53M | 4.62M |
| Effective Tax Rate % | 12.4% | 15.62% | 14.35% | -13.95% | 14.53% | -0.04% | -0.18% | 0.01% | -0.7% | -2.1% |
| Net Income | -12.55M▲ 0% | -19.73M▼ 57.2% | -31.11M▼ 57.7% | -123.85M▼ 298.0% | -142.09M▼ 14.7% | -142.1M▼ 0.0% | -148.84M▼ 4.7% | -208.38M▼ 40.0% | -220.66M▼ 5.9% | -224.8M▲ 0% |
| Net Margin % | -1035.48% | -1165.21% | -2976.49% | -4258.91% | -8285.36% | -9429.06% | -2402.95% | -12272.26% | -2180.45% | -439.68% |
| Net Income Growth % | -68.14% | -57.19% | -57.73% | -298.04% | -14.73% | -0% | -4.75% | -40.01% | -5.89% | 16.81% |
| Net Income (Continuing) | -12.55M | -19.73M | -44.75M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M | -224.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.91▲ 0% | -1.43▼ 57.1% | -0.99▲ 30.8% | -2.88▼ 190.9% | -2.76▲ 4.2% | -1.97▲ 28.6% | -1.57▲ 20.3% | -1.20▲ 23.6% | -0.87▲ 27.5% | -0.84▲ 0% |
| EPS Growth % | -68.52% | -57.14% | 30.77% | -190.91% | 4.17% | 28.62% | 20.3% | 23.57% | 27.5% | 30.58% |
| EPS (Basic) | -0.91 | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 | - |
| Diluted Shares Outstanding | 13.78M | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Basic Shares Outstanding | 13.78M | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AUTL Balance Sheet
Autolus Therapeutics plc (AUTL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'16 | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 30.93M | 142.48M | 199.14M | 249.26M | 193.98M | 346.95M | 425.77M | 275.3M | 660.93M | 514.58M |
| Cash & Short-Term Investments | 28.06M | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 588.02M | 367.41M |
| Cash Only | 28.06M | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 227.38M | 86.12M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 360.64M | 281.29M |
| Accounts Receivable | 2.18M | 4.73M | 9.26M | 30.52M | 29.68M | 68K | 28.98M | 1.05M | 48.24M | 91.36M |
| Days Sales Outstanding | 656.22 | 1.02K | 3.23K | 3.83K | 6.32K | 16.47 | 1.71K | 225.06 | 1.74K | 414.97 |
| Inventory | 0 | 0 | 2.21M | 0 | 0 | 0 | 0 | 0 | 4.14M | 27.72M |
| Days Inventory Outstanding | - | - | 16.69 | - | - | - | - | - | 10.71 | 30.71 |
| Other Current Assets | 0 | 0 | 717K | 279K | 0 | 27.83M | 2.02M | 26.05M | 5.32M | 4.88M |
| Total Non-Current Assets | 3.25M | 6.18M | 18.51M | 54.28M | 100.26M | 58.61M | 64.5M | 100.08M | 121.8M | 147.37M |
| Property, Plant & Equipment | 3.25M | 6.18M | 9.22M | 51.57M | 89.68M | 52.32M | 58.42M | 95.65M | 105.05M | 123.48M |
| Fixed Asset Turnover | 0.37x | 0.27x | 0.11x | 0.06x | 0.02x | 0.03x | 0.11x | 0.02x | 0.10x | 0.44x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.5M | 0 | 9.29M | 254K | 158K | 65K | 0 | 0 | 12.37M | 20.28M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -9.5M | 0 | 0 | 2.04M | 8.67M | 6.23M | 4.01M | 1.36M | 1.13M | 9.77M |
| Total Assets | 34.18M▲ 0% | 148.66M▲ 334.9% | 217.66M▲ 46.4% | 303.53M▲ 39.5% | 294.24M▼ 3.1% | 405.56M▲ 37.8% | 490.27M▲ 20.9% | 375.38M▼ 23.4% | 782.73M▲ 108.5% | 661.95M▲ 0% |
| Asset Turnover | 0.04x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x | 0.00x | 0.01x | 0.07x |
| Asset Growth % | 50.87% | 334.94% | 46.41% | 39.45% | -3.06% | 37.83% | 20.89% | -23.43% | 108.51% | 55.77% |
| Total Current Liabilities | 2.73M | 5.03M | 12.52M | 24.98M | 33.63M | 28.55M | 46.37M | 44.74M | 60.74M | 83.07M |
| Accounts Payable | 1.44M | 1.95M | 3.04M | 0 | 2.26M | 431K | 531K | 103K | 1.97M | 10.97M |
| Days Payables Outstanding | 1.1K | 703.95 | 22.94 | - | 6.12 | - | - | - | 5.1 | 9.94 |
| Short-Term Debt | 0 | 0 | 0 | 2.51M | 3.59M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 53K | 197K | 569K | 0 | 0 | 0 | 0 | 0 | 0 | 14.44M |
| Other Current Liabilities | 1.3M | 589K | 11.03M | 15.51M | 19.05M | 160K | 10.57M | 15.29M | 23.66M | 34.77M |
| Current Ratio | 11.31x | 28.31x | 15.91x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.88x | 10.88x |
| Quick Ratio | 11.31x | 28.31x | 15.73x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.81x | 10.81x |
| Cash Conversion Cycle | - | - | 3.23K | - | - | - | - | - | 1.75K | 435.74 |
| Total Non-Current Liabilities | 758K | 1.03M | 601K | 23.71M | 50.57M | 63.69M | 145.23M | 219.17M | 294.66M | 313.42M |
| Long-Term Debt | 0 | 0 | 221K | 0 | 0 | 47.02M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 188K | 265K | 221K | 23.71M | 50.57M | 16.55M | 19.22M | 47.91M | 49.63M | 226.63M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 570K | 763K | 159K | 0 | 0 | 128K | 126.02M | 171.26M | 245.03M | 743M |
| Total Liabilities | 3.49M | 6.06M | 12.52M | 48.69M | 84.2M | 92.24M | 191.6M | 263.91M | 355.4M | 396.5M |
| Total Debt | 188K | 265K | 221K | 26.22M | 54.16M | 68.01M | 24.26M | 52.97M | 52.63M | 65.83M |
| Net Debt | -27.87M | -136.81M | -189.08M | -185.21M | -99.92M | -242.32M | -358.18M | -186.6M | -174.75M | -20.29M |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.15x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.05x |
| Interest Coverage | - | - | -4541.96x | - | - | -127.04x | -16.05x | -3.99x | -25.98x | 25.85x |
| Total Equity | 30.69M▲ 0% | 142.6M▲ 364.7% | 205.14M▲ 43.9% | 254.84M▲ 24.2% | 210.03M▼ 17.6% | 313.32M▲ 49.2% | 298.67M▼ 4.7% | 111.47M▼ 62.7% | 427.32M▲ 283.3% | 265.45M▲ 0% |
| Equity Growth % | 48.2% | 364.7% | 43.86% | 24.23% | -17.58% | 49.18% | -4.67% | -62.68% | 283.34% | 168.39% |
| Book Value per Share | 2.23 | 10.35 | 6.50 | 5.92 | 4.07 | 4.35 | 3.14 | 0.64 | 1.67 | 1.00 |
| Total Shareholders' Equity | 30.69M | 142.6M | 205.14M | 254.84M | 210.03M | 313.32M | 298.67M | 111.47M | 427.32M | 265.45M |
| Common Stock | 577 | 1K | 1.28K | 120K | 121K | 4K | 8K | 8K | 12K | 12K |
| Retained Earnings | -28.18M | -47.9M | 163.84M | -237.15M | -379.24M | -521.34M | -670.18M | -878.56M | -1.1B | -1.3B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.65M | -3.85M | -76.27M | -8.69M | -5.86M | -8.45M | -38.9M | -28.99M | -29.17M | -4.92M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUTL Cash Flow Statement
Autolus Therapeutics plc (AUTL) cash flow — operating, investing & free cash flow history
| Line item | Sep'16 | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.85M | -16.36M | -25.85M | -101.48M | -117.76M | -117.86M | -112.31M | -145.59M | -206.27M | -206.27M |
| Operating CF Margin % | -812.62% | -966.33% | -2472.62% | -3489.82% | -6866.36% | -7820.9% | -1813.17% | -8574.03% | -2038.25% | - |
| Operating CF Growth % | -196.17% | -66.11% | -57.99% | -292.63% | -16.04% | -0.09% | 4.71% | -29.63% | -41.68% | -170.23% |
| Net Income | -12.55M | -19.73M | -31.11M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M | -224.8M |
| Depreciation & Amortization | 478K | 1.01M | 1.1M | 4.61M | 5.66M | 8.46M | 7.42M | 6.57M | 7.72M | 9.26M |
| Stock-Based Compensation | 2.26M | 3.15M | 5.03M | 30.21M | 20.11M | 9.94M | 12.01M | 11.2M | 15.47M | 17.23M |
| Deferred Taxes | 0 | 0 | -5.21M | -399K | -1.34M | -72K | -268K | -986K | -185K | 1.02M |
| Other Non-Cash Items | 1.2M | 5.17M | -1.07M | 4.14M | -1.5M | 1.77M | 13.39M | 45.72M | 15.04M | -53.9M |
| Working Capital Changes | -1.23M | -795K | 5.42M | -16.2M | 1.41M | 4.14M | 3.97M | 292K | -23.66M | -2.99M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -32.73M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.23M | 7.58M |
| Change in Payables | 507K | 434K | 8.65M | -1.45M | 1.44M | -1.82M | 22K | -509K | 1.59M | 9.15M |
| Cash from Investing | -1.85M | -2.88M | -7.65M | -18.67M | -14.68M | -8.86M | -10.84M | -10.99M | -394.55M | -311.67M |
| Capital Expenditures | -1.85M | -2.88M | -8.77M | -18.34M | -14.68M | -8.86M | -10.84M | -10.99M | -22.07M | -11.11M |
| CapEx % of Revenue | 153.05% | 169.88% | 839.09% | 630.71% | 856.03% | 587.72% | 175.02% | 647% | 218.13% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 1.13M | -327K | 0 | 0 | 0 | 0 | -12.74M | -400.49M |
| Cash from Financing | 32.22M | 127.69M | 117.49M | 108.86M | 74.42M | 284.06M | 223.61M | -883K | 589.55M | 27.46M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -3.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -115.92M | -79.75M | 38.16M | 59.76M | -883K | 39.58M | 27.46M |
| Net Change in Cash | 17.86M▲ 0% | 109.01M▲ 510.5% | 86.98M▼ 20.2% | -6.13M▼ 107.0% | -57.34M▼ 836.2% | 156.59M▲ 373.1% | 72.08M▼ 54.0% | -142.43M▼ 297.6% | -11.53M▲ 91.9% | -570.91M▲ 0% |
| Free Cash Flow | -11.7M▲ 0% | -19.24M▼ 64.4% | -34.62M▼ 80.0% | -120.15M▼ 247.1% | -132.44M▼ 10.2% | -126.72M▲ 4.3% | -123.15M▲ 2.8% | -156.57M▼ 27.1% | -241.09M▼ 54.0% | -278.04M▲ 0% |
| FCF Margin % | -965.68% | -1136.21% | -3311.71% | -4131.77% | -7722.39% | -8408.63% | -1988.2% | -9221.02% | -2382.31% | -543.8% |
| FCF Growth % | -186.33% | -64.35% | -79.97% | -247.07% | -10.23% | 4.32% | 2.82% | -27.14% | -53.98% | -35.22% |
| FCF per Share | -0.85 | -1.40 | -1.10 | -2.79 | -2.57 | -1.76 | -1.30 | -0.90 | -0.94 | -0.94 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x | 1.24x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 1.53M | 1.84M | 364K | 471K | 551K | 2.39M | 1.04M |
AUTL Key Ratios
Autolus Therapeutics plc (AUTL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -48.84% | -22.77% | -17.9% | -53.85% | -61.13% | -54.3% | -48.64% | -101.61% | -81.91% | -84.69% |
| Return on Invested Capital (ROIC) | -161.66% | -407.88% | -394.78% | -433.37% | -252.98% | -116.27% | -1865.44% | - | -204.08% | -204.08% |
| Gross Margin | 60.56% | 40.4% | -4520.4% | -3525.1% | -7765.19% | 100% | 100% | 100% | -1293.48% | -309.45% |
| Net Margin | -1035.48% | -1165.21% | -2976.49% | -4258.91% | -8285.36% | -9429.06% | -2402.95% | -12272.26% | -2180.45% | -439.68% |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x | 0.12x |
| Interest Coverage | - | - | -4541.96x | - | - | -127.04x | -16.05x | -3.99x | -25.98x | 25.85x |
| FCF Conversion | 0.78x | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x | 1.24x |
| Revenue Growth | 1187.83% | 39.69% | -38.26% | 178.19% | -41.02% | -12.13% | 311.02% | -72.59% | 496% | 406.67% |
AUTL SEC Filings & Documents
Autolus Therapeutics plc (AUTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AUTL Frequently Asked Questions
Autolus Therapeutics plc (AUTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Autolus Therapeutics plc (AUTL) reported $51.1M in revenue for fiscal year 2024. This represents a 54227% increase from $0.1M in 2015.
Autolus Therapeutics plc (AUTL) grew revenue by 496.0% over the past year. This is strong growth.
Autolus Therapeutics plc (AUTL) reported a net loss of $224.8M for fiscal year 2024.
Dividend & Returns
Autolus Therapeutics plc (AUTL) has a return on equity (ROE) of -81.9%. Negative ROE indicates the company is unprofitable.
Autolus Therapeutics plc (AUTL) had negative free cash flow of $278.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More AUTL
Autolus Therapeutics plc (AUTL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates